The New York Times is at it again. A year after its Editorial Board promoted flawed research on government rights to patented drugs as part of a price control plan, the Board floated the idea again, together with misinformation about the Bayh-Dole Act. Read more
Author: C-IP2
“No Combination Drug Patents Act” Stalls, but Threats to Innovation Remain
By Kevin Madigan & Sean O’Connor
This week, the Senate Judiciary Committee was to mark up a bill limiting patent eligibility for combination drug patents—new forms, uses, and administrations of FDA approved medicines. While the impetus was to curb so-called “evergreening” of drug patents, the effect would have been to stifle life-saving therapeutic innovations. Read more
CPIP Roundup – May 23, 2019
Sean O’Connor Joins George Mason University’s Scalia Law Faculty
O’Connor will lead the Center for the Protection of Intellectual Property and expand innovation and entrepreneurship programs.
Professor Sean O’Connor, noted innovation law scholar, is joining George Mason University’s Scalia Law faculty as a tenured full professor and Executive Director of the Center for Protection of Intellectual Property (CPIP). Read more
Sean O’Connor Joins George Mason University’s Scalia Law Faculty
O’Connor will lead the Center for the Protection of Intellectual Property and expand innovation and entrepreneurship programs.
Professor Sean O’Connor, noted innovation law scholar, is joining George Mason University’s Scalia Law faculty as a tenured full professor and Executive Director of the Center for Protection of Intellectual Property (CPIP). Read more
CPIP Roundup – March 19, 2019
Spotlight on Scholarship
There has been some excellent, recently-published scholarship from the growing network of scholars participating in our various programs and events. Here are five law review articles that you should check out!
Adam MacLeod, Public Rights After Oil States Energy, 95 Notre Dame L. Read more
Supreme Court to Assess USPTO’s Controversial Attorneys’ Fees Position
By Chris Katopis & Devlin Hartline
This week, the U.S. Supreme Court agreed to hear an important case concerning patent law procedures and the American legal system in general. In Iancu v. NantKwest, the Court asks, “Does all really mean all?” Read more
Qualcomm Founder Dr. Irwin M. Jacobs Delights Attendees at CPIP’s Sixth Annual Fall Conference
By Kathleen Wills*
On October 11-12, 2018, the Center for the Protection of Intellectual Property (CPIP) hosted its Sixth Annual Fall Conference at Antonin Scalia Law School in Arlington, Virginia. The theme of the conference was IP for the Next Generation of Technology, and it featured a number of panel discussions and presentations on how IP rights and institutions can foster the next great technological advances. Read more
Arts & Entertainment Advocacy Clinic Students File Amicus Brief in Brammer v. Violent Hues
By Rachelle Mortimer & Grant Ossler*
The Arts & Entertainment Advocacy Clinic at Antonin Scalia Law School recently filed an amicus brief in the Brammer v. Violent Hues case that is on appeal in the Fourth Circuit. The Clinic provides a unique opportunity for students interested in intellectual property and entertainment law. Read more
Proposed Misuse of Section 1498 Relies on the False Claim that Patents Are Not Property
By Kathleen Wills*
The question whether patents are property rights is a continuing and hotly debated topic in IP law. Despite an abundance of scholarship (see here, here, here, here, and here) detailing how intellectual property (“IP”) rights have long been equated with property rights in land and other tangible assets, critics often claim that this “propertarian” view of IP is a recent development. Read more
Proposal for Drug Price Controls is Legally Unprecedented and Threatens Medical Innovation
By Adam Mossoff, Sean O’Connor, & Evan Moore*
The price of the miracle drugs everyone uses today is cause for concern among people today. The President has commented on it. Some academics, lawyers, and policymakers have routinely called for the government to “do something” to lower prices. Read more